22 August 2019 in Journal of Clinical Pharmacy and Therapeutics
What is known and objective Statins are widely used worldwide in the prevention and treatment of coronary atherosclerotic heart disease and ischaemic stroke. However, in clinical application, statins have shown great individual differences in terms of the efficacy and safety, some of which are related to genetic factors. The purpose of this article was to summarize the recent advances about the correlation between gene polymorphisms and the efficacy/safety of statins. Methods We searched the databases including PharmGKB and PubMed (published before June 2019) using the keywords such as ‘statin’, ‘gene polymorphism’ and ‘SNP’ and obtained more than 100 articles. In this review, we described the clinical studies of genetic variants associated with both the efficacy and adverse reactions of statins. We also clarified the importance of taking pharmacogenetic variation into account to improve the clinical application of statins. Results and discussion The available data were collected and analysed to present the polymorphisms of candidate genes encoding the most promising proteins including SLCO1B1 (encoding uptake transporters); ABCB1, ABCC2, ABCG2 (encoding effluent transporter); APOE, APOA5 (encoding apolipoprotein); genes encoding cytochrome P450 enzyme system; KIF6, HMGCR, LDLR, LPA, PCSK9, COQ2, CETP, etc These genes were proved to be related to the pharmacodynamics and pharmacokinetics of statins, thus affecting the efficacy and safety. What is new and conclusion In this paper, the correlation between gene polymorphisms and the efficacy/safety of statins was summarized. The authors reached a consensus that the variants of the genes encoding uptake and effluent transporters have the most effect on the efficacy/safety of statins. It pointed out that it is desirable to do genetic testing of these transporter genes to reduce the incidence of myopathy or to achieve better outcomes before patients use statins, especially in the regions with high frequency of risk allele.
20 June 2025 in International Journal of Diabetes in Developing Countries
Background: Hypovolemia is one of the most common adverse events (AE) of SGLT2is, which is overlooked, especially in the elderly population. Objective: In this study, signal mining of AEs caused by SGLT2is was conducted, and the AE signals related to hypovolemia in the real world after marketing were statistically analyzed, so as to provide reference for reducing AEs and for clinical rational drug use. Methods: The FDA adverse event reporting system (FAERS) is an important data source for spontaneous reporting of AEs. A total of 46 quarterly data from 2013 Q1 to 2024 Q2 was extracted for analysis. In this study, disproportionality analysis was used to detect the signals of AEs and four methods including ROR, MHRA, BCPNN, and MGPS were combined. Results: 5017 AE reports related to SGLT2is induced hypovolemia were included in the analysis. According to the ROR value of signal mining, empagliflozin had a higher risk of hypovolemia (ROR = 13.87), while canagliflozin had a higher risk of hypovolemic shock (ROR = 3.40). In stratification analysis by sex, the risk of hypovolemia-related AEs was higher in females using canagliflozin than in males. The most significant differences were hypovolaemia (female ROR = 10.98 vs. male ROR = 5.56). When stratified by age, it showed that patients < 18 years old, 18–44 years old, and > 75 years old had a higher risk of hypovolemia-related AEs than other age groups. Conclusions: Hypovolemia related AEs caused by SGLT2is were found to be more common in women and elderly patients.